Advertisement

ESMO Congress | Conference

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

September 21st 2022

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15th 2022

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

PSA Decline After Lutetium Lu 177 Vipivotide Tetraxetan Treatment Prolongs Survival in PSMA-Positive mCRPC

September 13th 2022

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Lenvatinib/Pembrolizumab Combo Proves Safe, Effective for Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma

September 13th 2022

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors

September 12th 2022

GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.

Adagrasib With or Without Cetuximab Elicits Responses in Advanced KRAS G12C–Mutated CRC

September 12th 2022

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Ribociclib Plus Endocrine Therapy Provides Survival Benefit in Advanced HR+/HER2- Breast Cancer With Visceral Metastases

September 12th 2022

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab

September 12th 2022

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer

September 12th 2022

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRC

September 12th 2022

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12th 2022

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL

September 12th 2022

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC

September 12th 2022

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.

Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer

September 12th 2022

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

Two Years Post-operative ADT Plus Radiotherapy Improves MFS, Time to Salvage Therapy in Prostate Cancer

September 12th 2022

The addition of 24 months of androgen deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved time to salvage therapy in patients with prostate cancer.

Tucatinib Plus Trastuzumab Elicits Responses in Crossover Cohort in HER2+ mCRC

September 12th 2022

Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.

Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC

September 12th 2022

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.

Sotorasib Significantly Improves PFS Vs Docetaxel for KRAS G12C–Mutated NSCLC

September 12th 2022

Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.

Atezolizumab Shows Substantial OS Improvement in Platinum-Ineligible NSCLC

September 12th 2022

Atezolizumab led to an almost doubling in the rate of 2-year overall survival compared with vinorelbine or gemcitabine in patients with advanced platinum-ineligible non–small cell lung cancer.

Neoadjuvant Cemiplimab Elicits Encouraging Pathologic Complete Response in CSCC

September 12th 2022

Cemiplimab produced pathologic complete responses as a neoadjuvant treatment in more than half of patients with resectable, stage II to IV cutaneous squamous cell carcinoma.

Advertisement
Advertisement